BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 35538494)

  • 1. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
    Gu J; Huang W; Wang X; Zhang J; Tao T; Zheng Y; Liu S; Yang J; Chen ZS; Cai CY; Li J; Wang H; Fan Y
    Mol Cancer; 2022 May; 21(1):112. PubMed ID: 35538494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
    Qiu F; Chen J; Cao J; Diao F; Huang P
    Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
    Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
    Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
    Wu Y; Xu W; Yang Y; Zhang Z
    Ann Clin Lab Sci; 2021 May; 51(3):310-320. PubMed ID: 34162560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. circACTR2 attenuates gemcitabine chemoresiatance in pancreatic cancer through PTEN mediated PI3K/AKT signaling pathway.
    Xu C; Ye Q; Ye C; Liu S
    Biol Direct; 2023 Mar; 18(1):14. PubMed ID: 36991449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
    Sun ZY; Jian YK; Zhu HY; Li B
    Pathol Res Pract; 2019 Mar; 215(3):555-563. PubMed ID: 30661902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
    Zhao L; Zhang W; Zhang F
    Phytother Res; 2021 Jan; 35(1):278-288. PubMed ID: 32779800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
    Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
    Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
    Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
    Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells.
    Li Y; Zhai Z; Li H; Wang X; Huang Y; Su X
    Chem Biol Interact; 2019 May; 305():98-104. PubMed ID: 30929998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
    Huang L; Hu C; Cao H; Wu X; Wang R; Lu H; Li H; Chen H
    Cell Physiol Biochem; 2018; 47(2):747-758. PubMed ID: 29807360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
    Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
    Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway.
    Zhao F; Yang G; Qiu J; Liu Y; Tao J; Chen G; Su D; You L; Zheng L; Zhang T; Zhao Y
    Mol Carcinog; 2022 Sep; 61(9):839-850. PubMed ID: 35785493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
    Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
    Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer.
    Deng K; Zou F; Xu J; Xu D; Luo Z
    Mol Carcinog; 2024 Mar; 63(3):524-537. PubMed ID: 38197482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
    Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS
    Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zhu J; Lv J; Chen J; Zhang X; Ji Y
    Cell Cycle; 2020 Nov; 19(21):2851-2865. PubMed ID: 33064959
    [No Abstract]   [Full Text] [Related]  

  • 18. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
    Yu S; Wang M; Zhang H; Guo X; Qin R
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
    Wang L; Lin N; Li Y
    Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.
    Hu W; Liu Q; Pan J; Sui Z
    Biomed Pharmacother; 2018 Sep; 105():887-898. PubMed ID: 30021382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.